Message from the Chairman and CEO
Aiming to Resolve the Healthcare Issues Society Faces
In line with our mission of “shaping the advancement of healthcare,” which is defined in the “Sysmex Way,” the corporate philosophy of the Sysmex Group, Sysmex works to contribute to the development of healthcare and the healthy lives of people.
In recent years, advanced countries have been characterized by rapidly aging populations and increasingly diverse healthcare needs, including personalized medicine, while emerging markets have been marked by medical infrastructure developments and a rising quality of healthcare in line with economic development and population growth. Meanwhile, in addition to being affected by the three leading infectious diseases—HIV/AIDS, tuberculosis and malaria—developing countries have been facing various other types of infectious diseases, such as Ebola hemorrhagic fever. As a result, the healthcare environment is undergoing dramatic changes. International institutions, governments and companies must work together to address these issues. The Sustainable Development Goals (SDGs), adopted by the United Nations in September 2015, set 17 common goals for the international community in relation to society, the economy and the environment. Companies are being asked to undertake aggressive action to reach these goals.
Since the time of its founding, Sysmex has been involved with testing, playing an important role in disease prevention, early detection and determining courses of treatment. We have created new clinical value to enhance quality of life (QOL) among patients and other people who wish to be healthy, and we have striven to generate testing technologies to lighten the burden on professionals at medical institutions. In the field of in vitro diagnostics, we currently provide products, services and support in more than 190 countries and regions throughout the world.
With a view toward the realization of genomic medicine*1, since fiscal 2016 RIKEN GENESIS CO., LTD., has been a consolidated subsidiary which possesses advanced technologies and expertise in areas such as the analysis of genetic information. We are also conducting R&D aimed at the creation of next-generation diagnostic drugs that will make possible the early diagnosis and selection of treatment methods for dementia—a pressing issue in aging societies—and regular confirmation of the effects of treatment. At the same time, we are performing R&D on new diagnostic drugs that employ glycosylation markers*2 for the early detection and treatment monitoring of diseases originating from chronic hepatitis. Furthermore, as a global company we are endeavoring to raise the level of healthcare in emerging markets and developing countries and develop technologies useful in diagnosing malaria—one of the three most deadly infectious diseases. We are also working on organizing the healthcare providing structure together with international institutions such as the World Health Organization (WHO), the Global Health Innovative Technology Fund (GHIT Fund) and the Asian Conference on Communicable Diseases.
By resolving healthcare issues, Sysmex will continue to address the shared desire of all people around the world: to remain healthy.
※1 This type of medicine involves analyzing the relationship between genetic information and disease in order to predict the onset risk of diseases and aid in selecting the most effective course of treatment.
※2 The linked monosaccharides that link to the surface of a cell or protein in the blood
Formulating a New Mid-Term Management Plan Aimed at Realizing Sustainable Growth
Testing is expected to play a growing role in responding to increasingly diverse healthcare needs and other changes in the healthcare environment. Among its long-term management targets, Sysmex has set the management vision for 2020 of being “A Unique & Global Healthcare Testing Company” and is working toward more sophisticated and diverse testing. In recent years, we have been moving forward on collaborative development with research institutions, universities, hospitals and companies to create advanced and high-value testing and diagnostic technologies with a view to realizing personalized medicine.
In May 2017, Sysmex formulated a Group mid-term management plan concluding in the fiscal year ending March 31, 2020, to achieve its long-term management targets. Under this plan, we are enhancing our product lineup, expanding our global sales and service structure, developing highly competitive products that leverage our unique technologies, accelerating global business development, and investing in human resources and an IT foundation aimed at sustainable growth. Of these, we recognize that human resources are one of the most important drivers of corporate growth, so we are creating an environment designed to maximize and proactively develop each employee’s capabilities.
Identifying Priority Issues (Materiality)
In addition to contributing to the development of healthcare, Sysmex has engaged in a variety of CSR activities in accordance with its policy of building trust and confidence among stakeholders by fulfilling its corporate philosophy and core behaviors. We have recently identified priority issues aimed at realizing a sustainable society and sustainable growth for Sysmex. We have identified five priority domains through which we will instill trust and confidence in diverse stakeholders: “resolving healthcare issues through our products and services” as a company operating in the healthcare field; “providing responsible products and services,” which is important for our corporate activities; “realizing an attractive working environment,” “taking the environment into consideration,” and ensuring “governance.”
Sysmex will continue taking a proactive approach toward resolving the issues facing society through its business activities, aiming to contribute toward the realization of a sustainable society. I would like to ask for your continued support and understanding of our endeavors.